Skip to main content
Signal8

Evogene Ltd. (EVGN)

Sector: Agricultural Chemicals

Industry: Biotechnology

Evogene Ltd. logo

Evogene Ltd.

NASDAQ:EVGNHealthcare
AH+8.76%$0.3699
Close$0.3401-13.17%
Mkt Cap$6.14M
EV-
Float13.65M
O/S18.05M
VOL254K sh
$ Vol$92K
RVOL0.47×
Inst Own2.3%
Net Cash/Sh-
Dilution
Evogene Ltd. logoNASDAQ:EVGNAH$0.3699+8.76%
Historical Data
DateOpenHighLowCloseVolume
Nov 17, 20260.38230.39220.33010.3401254,086
Nov 16, 20260.38000.44040.36470.3917149,021
Nov 13, 20260.36800.38900.35010.371062,593
Nov 12, 20260.36100.36990.35370.361049,007
Nov 11, 20260.34460.43000.33400.3954372,130
Nov 10, 20260.28430.41500.28000.37202,364,146
Nov 9, 20260.26500.29980.26500.2875132,798
Nov 6, 20260.27900.28190.25030.2710412,935
Nov 5, 20260.34030.34470.30000.32967,677,229
Nov 4, 20260.35030.36420.35030.356813,187
Nov 3, 20260.36100.38980.35240.359923,210
Nov 2, 20260.36690.37420.36000.361025,394
Oct 30, 20260.37750.38000.36530.374614,767
Oct 29, 20260.36100.38110.36040.380413,846
Oct 28, 20260.36000.38700.35460.374440,403
Oct 27, 20260.36300.36380.34650.36389,430
Oct 26, 20260.37000.37000.36040.370039,606
Oct 23, 20260.36520.37260.35990.36419,397
Oct 22, 20260.35940.38790.35940.375910,108
Oct 21, 20260.37410.38000.36800.370438,394
Analyst Coverage
Analyst Coverage
ConsensusBuy
Price Target
Not available
Ratings Distribution
BUY
4
HOLD
0
SELL
0
TOTAL4
Insider Trades
InsiderTypeShares
RECANATI LEON profile photoRECANATI LEONPurchase460.0K
RECANATI LEON profile photoRECANATI LEONPurchase800.0K
Tarcic Gabi profile photoTarcic GabiPurchase1.1K
Shareholders
2.3%
Institutional
(12)
0.0%
Insiderⓘ
(2)
24.4%
5%+ Owners
(2)
73.2%
Unattributed (incl. retail)ⓘ
Institutional2.3%
Insider0.0%
5%+ Beneficial24.4%
Unattributed (incl. retail)73.2%
Top Shareholders
NameShares%
L.I.A. Pure Capital Ltd. logo
L.I.A. Pure Capital Ltd.
· joint filing· may incl. warrants· filed Oct 2026
3.1M16.9%
RECANATI LEON logo
RECANATI LEON
· may incl. warrants· filed Sep 2026
1.4M7.5%
CITADEL ADVISORS LLC logo
CITADEL ADVISORS LLC
305.5K1.7%
XTX Topco Ltd logo
XTX Topco Ltd
101.9K0.6%
JANE STREET GROUP, LLC logo
JANE STREET GROUP, LLC
10.8K0.1%
ELDAD YARON profile photo
ELDAD YARON
Chief Financial Officer
4.1K0.0%
MORGAN STANLEY logo
MORGAN STANLEY
2.7K0.0%
Tarcic Gabi profile photo
Tarcic Gabi
Chief Development Officer
1.1K0.0%
BNP PARIBAS FINANCIAL MARKETS logo
BNP PARIBAS FINANCIAL MARKETS
1.1K0.0%
Daytona Street Capital LLC logo
Daytona Street Capital LLC
5340.0%
Sources: 13F, Form 4, 13D/13GO/S: 18.1M · as of 31 Aug 2026 · SEC filings
Insiders & Institutional Holders
About

Evogene Ltd., along with its subsidiaries, operates as a computational biology firm.

Its core activity involves the discovery and advancement of products across diverse life-science sectors, such as human health and agriculture, primarily leveraging its proprietary Computational Predictive Biology (CPB) platform. This platform, built on deep biological insights, big data analytics, and artificial intelligence, is engineered to digitally identify and strategically guide the creation of life-science solutions derived from microbes, small molecules, and genetic components.

The company's operations are structured into three primary divisions: Agriculture, Human Health, and Industrial Applications. Within the Agriculture division, Evogene works on seed traits, agricultural chemicals, and biological products aimed at improving plant yields, with efforts spanning critical crops like corn, soybean, wheat, rice, and cotton. The Industrial Applications segment focuses on enhancing castor bean seeds for use as a raw material in various industrial applications. Meanwhile, the Human Health segment is dedicated to uncovering and developing human microbiome-based treatments for conditions including immuno-oncology, gastrointestinal disorders, and antimicrobial-resistant infections. Beyond these core areas, Evogene also delivers medical cannabis products.

The company maintains a global presence, conducting operations in the United States, Israel, Brazil, and other international markets.

It has forged key partnerships and licensing agreements with leading agricultural enterprises, such as BASF SE, Corteva, and Bayer.

Additionally, its subsidiary, Canonic Ltd., collaborates with Cannbit Ltd. on the development of innovative medical cannabis offerings. Established in 1999, Evogene Ltd. is based in Rehovot, Israel.

Key Metrics
Market Cap$6.14M
Enterprise Value--
P/E Ratio--
Est. Net Cash/Share--
Institutional Ownership2.35%

based on 18.05M shares outstanding

SectorHealthcare
IndustryBiotechnology
ExchangeNASDAQ
CountryILIL
IPO DateOct 15, 2010
Shares Outstanding18.05M
Authorized Shares
Float13.65M
52-Week Range
$0.2503$1.26
$0.3401(9th percentile)
Volume
Average Daily Volume538.23K
254.09K today vs 538.23K avg(-53%)

30d Avg

538.23K

60d Avg

2.04M

90d Avg

1.44M

Earnings
Dividend History
No dividend history available
Compliance Status
Loading compliance data...

Signal8's dilution snapshot of EVGN as of Dec 31, 2025 records an effective F-3 shelf registration (effective Apr 15, 2026), an at-the-market sales agreement dated Jun 11, 2026 and 2 outstanding warrant series, from SEC filings. Evogene Ltd. (NASDAQ: EVGN) traded at $0.3401 on Nov 17, 2026, down 13.17% from the previous close of $0.3917. 52-week range: $0.2503 to $1.26. The company is in the Healthcare sector (Biotechnology).